Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietObesityBG ControlType 2 DiabetesPreventionGenetics of DiabetesOncologyPathologyPublic HealthIssue 663

Mechanism that Links Diabetes and Obesity with Cancer Discovered

Sustained high levels of sugars damage our cells and can….

Advertisement

Scientists led by Dr. Custodia Garcia-Jimenez at the University Rey Juan Carlos in Madrid have uncovered a key mechanism that links obesity and diabetes with cancer: high sugar levels, which increase the activity of a gene widely implicated in cancer progression.

Dr. Jimenez studied how cells in the intestine respond to sugars and signal to the pancreas to release insulin, the key hormone that controls blood sugar levels. Sugars in the intestine trigger cells to release a hormone called GIP that enhances insulin release by the pancreas.

In a published study, Dr. Garcia Jimenez's team showed that the ability of the intestinal cells to secrete GIP is controlled by a protein called β-catenin, and that the activity of β-catenin is strictly dependent on sugar levels.

Increased activity of β-catenin is known to be a major factor in the development of many cancers and can make normal cells immortal, a key step in early stages of cancer progression. The study demonstrates that high (but not normal) sugar levels induce nuclear accumulation of β-catenin and lead to cell proliferation. The β-catenin changes, the molecules involved, and the diversity of cancer cells susceptible to these changes are identified.

Dr. Custodia García said, "We were surprised to realize that changes in our metabolism caused by dietary sugar impact our cancer risk. We are now investigating what other dietary components may influence our cancer risk. Changing diet is one of the easiest prevention strategies that can potentially save a lot of suffering and money."

Colin Goding, Professor of Oncology at the University of Oxford, UK, said, "Previously we were unsure about how increased blood sugar found in diabetes and obesity could increase cancer risk. This study identifies a key molecular mechanism through which high blood glucose would predispose to cancer. It opens the way for potential novel therapies aimed at reducing cancer risk in the obese and diabetic populations."

Estimations published by the World Health Organization: obesity predisposes to diabetes and its prevalence is doubling every 20 years worldwide. More than 1 in 10 adults worldwide (12%) are obese (BMI greater than 30). One in 6 children in the UK and Spain suffer obesity.

More than half (63%) of premature deaths worldwide are due to non-communicable diseases of which cancer and diabetes are among the 4 most frequent causes. At least 1 in 3 of the main cancers (27-39%) can be prevented by improving diet, physical activity and body composition.

Molecular Cell Jan 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2013 and appeared in  DietObesityBG ControlType 2 DiabetesPreventionGenetics of DiabetesOncologyPathologyPublic HealthIssue 663

Past five issues: Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 | GLP-1 Special Editions August 2015 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Bromocriptine for High Dose Insulin Therapy Type 2 Patients
Posted July 23, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Guy Pupp, DPM, FACFAS

Category: Diabetic Foot
Credits:
 1.0